Literature DB >> 31801899

Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs.

Erin P Balogh1, Andrew B Bindman2, S Gail Eckhardt3, Susan Halabi4, R Donald Harvey5, Ishmael Jaiyesimi6, Rebecca Miksad7, Harold L Moses8, Sharyl J Nass9, Richard L Schilsky10, Steven Sun11, Josephine M Torrente12, Katherine E Warren13.   

Abstract

A number of important drugs used to treat cancer-many of which serve as the backbone of modern chemotherapy regimens-have outdated prescribing information in their drug labeling. The Food and Drug Administration is undertaking a pilot project to develop a process and criteria for updating prescribing information for longstanding oncology drugs, based on the breadth of knowledge the cancer community has accumulated with the use of these drugs over time. This article highlights a number of considerations for labeling updates, including selecting priorities for updating; data sources and evidentiary criteria; as well as the risks, challenges, and opportunities for iterative review to ensure prescribing information for oncology drugs remains relevant to current clinical practice.
© 2019 The Authors. The Oncologist published by Wiley Periodicals, Inc. on behalf of AlphaMed Press.

Keywords:  Cancer; Drug approval; Drug legislation; Drug prescriptions; Pharmaceutical research

Year:  2019        PMID: 31801899     DOI: 10.1634/theoncologist.2019-0698

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  5 in total

1.  A national cancer clinical trials system for the 21st century: reinvigorating the NCI Cooperative Group Program.

Authors:  John F Scoggins; Scott D Ramsey
Journal:  J Natl Cancer Inst       Date:  2010-08-03       Impact factor: 13.506

2.  Outdated Prescription Drug Labeling: How FDA-Approved Prescribing Information Lags Behind Real-World Clinical Practice.

Authors:  Michael B Shea; Mark Stewart; Hugo Van Dyke; Linda Ostermann; Jeff Allen; Ellen Sigal
Journal:  Ther Innov Regul Sci       Date:  2018-03-05       Impact factor: 1.778

3.  Using observational data from registries to compare treatments: the fallacy of omnimetrics.

Authors:  S B Green; D P Byar
Journal:  Stat Med       Date:  1984 Oct-Dec       Impact factor: 2.373

4.  Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement.

Authors:  Edward S Kim; Suanna S Bruinooge; Samantha Roberts; Gwynn Ison; Nancy U Lin; Lia Gore; Thomas S Uldrick; Stuart M Lichtman; Nancy Roach; Julia A Beaver; Rajeshwari Sridhara; Paul J Hesketh; Andrea M Denicoff; Elizabeth Garrett-Mayer; Eric Rubin; Pratik Multani; Tatiana M Prowell; Caroline Schenkel; Marina Kozak; Jeff Allen; Ellen Sigal; Richard L Schilsky
Journal:  J Clin Oncol       Date:  2017-10-02       Impact factor: 44.544

5.  Harnessing the Power of Real-World Evidence (RWE): A Checklist to Ensure Regulatory-Grade Data Quality.

Authors:  Rebecca A Miksad; Amy P Abernethy
Journal:  Clin Pharmacol Ther       Date:  2017-12-06       Impact factor: 6.875

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.